[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Toung TJ, Tyler B, Brem H, Traystman RJ, Hurn PD, Bhardwaj A: Hypertonic saline ameliorates cerebral edema associated with experimental brain tumor. J Neurosurg Anesthesiol; 2002 Jul;14(3):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, hypertonic saline (HS) has received attention as an osmotic agent in the treatment of cerebral edema from diverse causes.
  • 9L gliosarcoma, propagated as a solid flank tumor, was implanted intracranially over the left hemisphere in adult female Fischer 344 rats (180-220 g).
  • [MeSH-major] Brain Edema / drug therapy. Brain Edema / etiology. Brain Neoplasms / complications. Saline Solution, Hypertonic / therapeutic use
  • [MeSH-minor] Animals. Body Water / metabolism. Brain Chemistry / drug effects. Diuretics / therapeutic use. Diuretics, Osmotic / therapeutic use. Female. Furosemide / therapeutic use. Mannitol / therapeutic use. Neoplasm Transplantation. Osmolar Concentration. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FUROSEMIDE .
  • Hazardous Substances Data Bank. D-MANNITOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12172290.001).
  • [ISSN] 0898-4921
  • [Journal-full-title] Journal of neurosurgical anesthesiology
  • [ISO-abbreviation] J Neurosurg Anesthesiol
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS20020; United States / NINDS NIH HHS / NS / NS33668; United States / NCI NIH HHS / CA / U01 CA52857
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics; 0 / Diuretics, Osmotic; 0 / Saline Solution, Hypertonic; 3OWL53L36A / Mannitol; 7LXU5N7ZO5 / Furosemide
  •  go-up   go-down


2. Grosu AL, Weber WA, Franz M, Stärk S, Piert M, Thamm R, Gumprecht H, Schwaiger M, Molls M, Nieder C: Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Oct 1;63(2):511-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To develop a valid treatment strategy for recurrent high-grade gliomas using stereotactic hypofractionated reirradiation based on biologic imaging and temozolomide.
  • PATIENTS AND METHODS: The trial included a total of 44 patients with recurrent high-grade gliomas (1 patient with anaplastic oligodendroglioma, 8 with anaplastic astrocytoma, 33 with glioblastoma multiforme, and 2 with gliosarcoma) after previous surgery and postoperative conventional radiotherapy +/- chemotherapy.
  • Median survival time were 11 months for patients who received SFRT based on biologic imaging plus temozolomide and significantly lower, 6 months for patients treated with SFRT without biologic imaging, without temozolomide or without both (p = 0.008, log rank).
  • CONCLUSION: This is the first study of biologic imaging optimized SFRT plus temozolomide in recurrent high-grade gliomas.
  • [MeSH-major] Glioma / drug therapy. Glioma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radionuclide imaging. Astrocytoma / radiotherapy. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Dose Fractionation. Female. Glioblastoma / drug therapy. Glioblastoma / radionuclide imaging. Glioblastoma / radiotherapy. Gliosarcoma / drug therapy. Gliosarcoma / radionuclide imaging. Gliosarcoma / radiotherapy. Humans. Male. Methionine. Middle Aged. Oligodendroglioma / drug therapy. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / radiotherapy. Positron-Emission Tomography / methods. Prospective Studies. Statistics, Nonparametric. Stereotaxic Techniques. Tomography, Emission-Computed, Single-Photon / methods. alpha-Methyltyrosine

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168843.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 658-48-0 / alpha-Methyltyrosine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; AE28F7PNPL / Methionine
  •  go-up   go-down


3. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S: Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol; 2001 Feb;12(2):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One hundred twenty-eight patients were histologically confirmed with GBM or gliosarcoma (GS) by independent central review.
  • The use of this drug should be explored further in an adjuvant setting and in combination with other agents.

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2001 Feb;12(2):149-50 [11300316.001]
  • (PMID = 11300335.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


Advertisement
4. Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol; 2009 Feb 1;27(4):579-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
  • PURPOSE: This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy (XRT) and temozolomide to treat glioblastoma multiforme (GBM) and gliosarcoma.
  • PATIENTS AND METHODS: Sixty-five eligible adults with newly diagnosed GBM or gliosarcoma were enrolled.
  • We intended to treat patients not currently treated with enzyme-inducing antiepileptic drugs (EIAEDs) with 100 mg/d of erlotinib during XRT and 150 mg/d after XRT.

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2005 Nov 10;353(19):2012-24 [16282176.001]
  • [Cites] Clin Cancer Res. 2005 Nov 1;11(21):7841-50 [16278407.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1192-9 [16626884.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 May;61(6):1059-67 [17694310.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1442-53 [10598712.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1383-7 [10728703.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):353-7 [15380566.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4309-13 [1584765.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):207-18 [10454198.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1454-9 [15817350.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):880-7 [15956649.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • (PMID = 19075262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / 2 P50 CA097257
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride
  • [Other-IDs] NLM/ PMC2645859
  •  go-up   go-down


5. Fabel K, Dietrich J, Hau P, Wismeth C, Winner B, Przywara S, Steinbrecher A, Ullrich W, Bogdahn U: Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer; 2001 Oct 1;92(7):1936-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Resistance to chemotherapeutic agents and poor blood-brain barrier penetration are major limitations in the treatment of malignant glioma.
  • To improve drug delivery across the blood-brain barrier, the authors used doxorubicin as liposomal encapsulated formulation (Caelyx, Scheringh-Plough, Munich, Germany) in therapy of recurrent malignant glioma.
  • Of these, 13 patients could be evaluated, including 6 patients with glioblastoma, 1 patient with gliosarcoma and 6 patients with anaplastic astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Central Nervous System Neoplasms / drug therapy. Doxorubicin / therapeutic use. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Administration Schedule. Female. Humans. Liposomes. Male. Middle Aged. Remission Induction. Survival Analysis

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11745268.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


6. Murphy S, Boyle FM, Davey RA, Gu XQ, Mather LE: Enantioselectivity of thalidomide serum and tissue concentrations in a rat glioma model and effects of combination treatment with cisplatin and BCNU. J Pharm Pharmacol; 2007 Jan;59(1):105-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thalidomide is currently under evaluation as an anti-angiogenic agent in cancer treatment, alone and in combination with cytotoxic agents.
  • Thalidomide is a racemate with known pharmacologic and pharmacokinetic enantioselectivity.
  • Adult female F344 rats were implanted with 9L gliosarcoma tumours intracranially, subcutaneously (flank), or both.
  • The consistency of the enantiomer concentration ratios across treatments strongly suggests that the favourable antitumour outcomes from interactions between thalidomide and the cytotoxic agents BCNU and cisplatin did not have altered enantioselectivity of thalidomide pharmacokinetics as their basis.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carmustine / administration & dosage. Cisplatin / administration & dosage. Glioma / metabolism. Immunosuppressive Agents / pharmacokinetics. Thalidomide / pharmacokinetics
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols. Disease Models, Animal. Female. Neoplasm Transplantation. Rats. Rats, Inbred F344. Stereoisomerism. Tissue Distribution

  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227627.001).
  • [ISSN] 0022-3573
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


7. Galasso JM, Stegman LD, Blaivas M, Harrison JK, Ross BD, Silverstein FS: Experimental gliosarcoma induces chemokine receptor expression in rat brain. Exp Neurol; 2000 Jan;161(1):85-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental gliosarcoma induces chemokine receptor expression in rat brain.
  • We used an established experimental gliosarcoma model, induced by intracranial transplantation of cultured 9L cells into adult rat brain, to test this hypothesis.
  • [MeSH-major] Autoantigens / genetics. Brain Neoplasms / immunology. Chemokine CCL2. Gliosarcoma / immunology. Receptors, Chemokine. Receptors, Cytokine / genetics
  • [MeSH-minor] Animals. Blotting, Western. Brain Chemistry / genetics. Brain Chemistry / immunology. DNA Primers. Gene Expression Regulation, Neoplastic / drug effects. Lipopolysaccharides / pharmacology. Macrophages / immunology. Magnetic Resonance Imaging. Male. Microglia / physiology. Neoplasm Transplantation. RNA, Messenger / analysis. Rats. Rats, Inbred F344. Receptors, CCR2

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Academic Press.
  • (PMID = 10683275.001).
  • [ISSN] 0014-4886
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS31054; United States / NINDS NIH HHS / NS / NS35059
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Autoantigens; 0 / Ccl2 protein, rat; 0 / Ccr2 protein, rat; 0 / Chemokine CCL2; 0 / DNA Primers; 0 / Lipopolysaccharides; 0 / RNA, Messenger; 0 / Receptors, CCR2; 0 / Receptors, Chemokine; 0 / Receptors, Cytokine
  •  go-up   go-down


8. Ribalta T, McCutcheon IE, Neto AG, Gupta D, Kumar AJ, Biddle DA, Langford LA, Bruner JM, Leeds NE, Fuller GN: Textiloma (gossypiboma) mimicking recurrent intracranial tumor. Arch Pathol Lab Med; 2004 Jul;128(7):749-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resorbable and nonresorbable hemostatic agents have been reported to cause symptomatic mass lesions, most commonly following intra-abdominal surgery.
  • Histologic examination typically shows a core of degenerating hemostatic agent surrounded by an inflammatory reaction.
  • Each agent exhibits distinctive morphologic features that often permit specific identification.
  • OBJECTIVES: The aims of this study were to (1) identify cases of histologically proven cases of textiloma in neurosurgical operations, (2) characterize the specific hemostatic agent associated with textiloma formation, and (3) characterize the preoperative magnetic resonance imaging appearance of textiloma.
  • The primary neoplasm was different in each case and included pituitary adenoma, tanycytic ependymoma, anaplastic astrocytoma, gliosarcoma, and oligodendroglioma.
  • Textilomas included all categories of resorbable hemostatic agent.
  • Microfibrillar collagen (Avitene) textilomas were associated with a striking eosinophil infiltration that was not seen with any other hemostatic agent.
  • CONCLUSIONS: Hemostatic agents may produce clinically symptomatic, radiologically apparent mass lesions.
  • [MeSH-minor] Adolescent. Adult. Cellulose, Oxidized. Collagen. Cotton Fiber. Diagnosis, Differential. Female. Gelatin Sponge, Absorbable. Hemostatics. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Radiation Injuries / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15214828.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Hemostatics; 82347-53-3 / Surgicel; 9007-34-5 / Collagen
  •  go-up   go-down


9. Levin VA, Phuphanich S, Yung WK, Forsyth PA, Maestro RD, Perry JR, Fuller GN, Baillet M: Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol; 2006 Jul;78(3):295-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Because raised matrix metalloprotease (MMP) levels are associated with glioma invasion and angiogenesis, we tested the efficacy of marimastat (MT) an orally active drug that can reduce MMP levels, in patients with gliomas.
  • CONCLUSION: MT does not improve survival in patients with glioblastoma or gliosarcoma following surgery and radiotherapy.
  • Therefore, single-agent MT appears unwarranted; however, MT in combination with cytotoxic chemotherapy may be warranted, as suggested by observations in our study and other studies.
  • [MeSH-major] Brain Neoplasms / drug therapy. Enzyme Inhibitors / therapeutic use. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Hydroxamic Acids / therapeutic use. Matrix Metalloproteinase Inhibitors
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Double-Blind Method. Female. Humans. Male. Matrix Metalloproteinases / metabolism. Middle Aged. Musculoskeletal Diseases / chemically induced. Quality of Life. Survival Analysis. Treatment Failure

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3878-84 [11051233.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):29-34 [8613832.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):12-8 [8521611.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):657-72 [12209155.001]
  • [Cites] Clin Exp Metastasis. 1996 Jan;14(1):35-42 [8521615.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Biol Chem. 1997 Nov 14;272(46):28823-5 [9360944.001]
  • [Cites] Clin Pharmacol Ther. 1974 May;15(5):443-53 [4597226.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):329-35 [894339.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):198-219 [8153665.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23349-57 [10438512.001]
  • [Cites] Adv Enzyme Regul. 1995;35:293-301 [7572350.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] J Biol Chem. 1999 Oct 8;274(41):29568-71 [10506224.001]
  • [Cites] Cancer. 1995 Mar 1;75(5):1151-61 [7850714.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1481-91 [10735896.001]
  • [Cites] Ann Oncol. 1995 Dec;6(10):967-74 [8750146.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1101-9 [9607566.001]
  • [Cites] J Biol Chem. 2000 Dec 29;275(52):41415-23 [10998420.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):639-45 [12680160.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1383-8 [11870183.001]
  • [Cites] Oncogene. 2000 Dec 27;19(56):6642-50 [11426650.001]
  • (PMID = 16636750.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Hydroxamic Acids; 0 / Matrix Metalloproteinase Inhibitors; D5EQV23TDS / marimastat; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


10. Hau P, Kunz-Schughart LA, Rümmele P, Arslan F, Dörfelt A, Koch H, Lohmeier A, Hirschmann B, Müller A, Bogdahn U, Bosserhoff AK: Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. J Neurooncol; 2006 Mar;77(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression levels of both proteins were evaluated and correlated with each other, time to progression and molecular and morphological markers of invasion.
  • We could not detect a correlation of one of the proteins with time to progression.
  • [MeSH-major] Brain Neoplasms / metabolism. Extracellular Matrix Proteins / metabolism. Glioma / metabolism. Tenascin / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Child. Disease Progression. Gene Expression Regulation, Neoplastic. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Gliosarcoma / genetics. Gliosarcoma / metabolism. Gliosarcoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. RNA, Messenger / analysis. Time Factors. Transforming Growth Factor beta1. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):362-9 [11920587.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):937-42 [15033492.001]
  • [Cites] Curr Opin Oncol. 2003 May;15(3):197-203 [12778011.001]
  • [Cites] Radiother Oncol. 2004 Sep;72(3):297-303 [15450728.001]
  • [Cites] Surg Neurol. 2000 Sep;54(3):235-40 [11118570.001]
  • [Cites] Acta Neurochir Suppl. 2003;88:163-7 [14531574.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):430-46 [15136790.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):1107-10 [11496325.001]
  • [Cites] Oncogene. 2004 Mar 4;23(9):1656-67 [15001984.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Mar;54(2):236-44 [7876891.001]
  • [Cites] Cancer Treat Res. 2004;117:169-90 [15015561.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1029-40 [10515226.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):251-8 [10861501.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2660-8 [11980665.001]
  • [Cites] Microsc Res Tech. 2001 Feb 15;52(4):401-10 [11170299.001]
  • [Cites] Acta Neuropathol. 1989;78(2):189-93 [2750489.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3622-33 [15116096.001]
  • [Cites] Int J Cancer. 1991 Aug 19;49(1):129-39 [1874566.001]
  • [Cites] Br J Cancer. 1994 Aug;70(2):199-203 [8054266.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):177-85 [11716069.001]
  • [Cites] Acta Neuropathol. 2002 Jul;104(1):85-91 [12070669.001]
  • [Cites] Biol Chem. 2002 Sep;383(9):1407-13 [12437133.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • (PMID = 16292494.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / RNA, Messenger; 0 / TGFB1 protein, human; 0 / Tenascin; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


11. Zhang Z, Jiang Q, Jiang F, Ding G, Zhang R, Wang L, Zhang L, Robin AM, Katakowski M, Chopp M: In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor. Neuroimage; 2004 Sep;23(1):281-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo magnetic resonance imaging tracks adult neural progenitor cell targeting of brain tumor.
  • The labeled neural progenitor cells and MSCs were transplanted to rats via the cisterna magna and a tail vein, respectively, 1 week after 9L-gliosarcoma cell implantation.
  • Three-dimensional (3D) gradient echo and contrast agent images revealed dynamic migration of adult neural progenitor cells and MSCs detected by loss of MRI signals towards tumor mass and infiltrated tumor cells.
  • These results demonstrate that the MRI technique provides a sensitive method for in vivo assessment of grafted cells targeting tumor mass and infiltrated tumor cells and that adult neural progenitor cells and MSCs can target tumor aggregates in the brain.
  • [MeSH-major] Bone Marrow Cells / pathology. Bone Marrow Transplantation. Brain Neoplasms / pathology. Gliosarcoma / pathology. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Magnetic Resonance Imaging. Neoplasm Transplantation. Nerve Tissue / transplantation. Stem Cells / pathology. Stromal Cells / transplantation. Tumor Cells, Cultured / physiology
  • [MeSH-minor] Animals. Cell Aggregation / physiology. Humans. Male. Neovascularization, Pathologic / pathology. Rats. Rats, Inbred F344. Tumor Stem Cell Assay


12. Bax DA, Gaspar N, Little SE, Marshall L, Perryman L, Regairaz M, Viana-Pereira M, Vuononvirta R, Sharp SY, Reis-Filho JS, Stávale JN, Al-Sarraj S, Reis RM, Vassal G, Pearson AD, Hargrave D, Ellison DW, Workman P, Jones C: EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell lines. Clin Cancer Res; 2009 Sep 15;15(18):5753-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The epidermal growth factor receptor (EGFR) is amplified and overexpressed in adult glioblastoma, with response to targeted inhibition dependent on the underlying biology of the disease.
  • No kinase or extracellular domain mutations were observed; however, 6 of 35 (17%) cases harbored the EGFRvIII deletion, including two anaplastic oligodendrogliomas and a gliosarcoma overexpressing EGFRvIII in the absence of gene amplification and coexpressing platelet-derived growth factor receptor alpha.
  • Pediatric glioblastoma cells transduced with wild-type or deletion mutant EGFRvIII were not rendered more sensitive to erlotinib despite expressing wild-type PTEN.
  • [MeSH-major] Glioma / drug therapy. Glioma / genetics. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Sequence Deletion
  • [MeSH-minor] Adolescent. Blotting, Western. Cell Proliferation / drug effects. Child. Erlotinib Hydrochloride. Humans. Prognosis. Quinazolines / pharmacology. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2009 Nov 15;15(22):7110
  • (PMID = 19737945.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C1178/A10294; United Kingdom / Cancer Research UK / / C309/A2187; United Kingdom / Cancer Research UK / / C309/A8274
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 0 / epidermal growth factor receptor VIII; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


13. Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Vredenburgh JJ, Desjardins A, Gururangan S, Badruddoja M, Dowell JM, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol; 2006 Jan 1;24(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: In this phase II trial, 100 mCi of 131I-m81C6 was injected directly into the surgically created resection cavity (SCRC) of 43 patients with recurrent malignant glioma (glioblastoma multiforme [GBM], n = 33; anaplastic astrocytoma [AA], n = 6; anaplastic oligodendroglioma [AO], n = 2; gliosarcoma [GS], n = 1; and metastatic adenocarcinoma, n = 1) followed by chemotherapy.
  • We are now conducting a phase II trial, approved by the US Food and Drug Administration, using patient-specific 131I-m81C6 dosing, to deliver 44 Gy to the SCRC followed by standardized chemotherapy.
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Oncol. 2006 Mar 20;24(9):1484. Guruangan, Sri [corrected to Gururangan, Sridharan]
  • (PMID = 16382120.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1-P50-CA108786-01; United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / MO1 RR 30; United States / NINDS NIH HHS / NS / NS20023
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Iodine Radioisotopes; 0 / Tenascin
  •  go-up   go-down


14. Butowski N, Chang SM, Lamborn KR, Polley MY, Parvataneni R, Hristova-Kazmierski M, Musib L, Nicol SJ, Thornton DE, Prados MD: Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Neuro Oncol; 2010 Jun;12(6):608-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We conducted a phase I study to determine the safety and recommended phase II dose of enzastaurin (oral inhibitor of the protein kinase C-beta [PKCbeta] and the PI3K/AKT pathways) when given in combination with radiation therapy (RT) plus temozolomide to patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
  • Patients with Karnofsky performance status > or =60 and no enzyme-inducing anti-epileptic drugs received RT (60 Gy) over 6 weeks, concurrently with temozolomide (75 mg/m(2) daily) followed by adjuvant temozolomide (200 mg/m(2)) for 5 days/28-d cycle.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Cohort Studies. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Female. Humans. Indoles / administration & dosage. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Invest New Drugs. 1999;17(3):227-40 [10665476.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1275-9 [19188675.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Clin Cancer Res. 2003 Aug 15;9(9):3369-75 [12960124.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40 [14593497.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):816-26 [9669344.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4413-8 [10485491.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47720-5 [15364915.001]
  • [Cites] Oncogene. 2004 Dec 2;23(56):9062-9 [15489897.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7462-9 [16103100.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4092-9 [16943527.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):689-700 [17108987.001]
  • [Cites] Neuro Oncol. 2007 Jan;9(1):47-52 [17108062.001]
  • [Cites] Ann Neurol. 2007 Feb;61(2):153-61 [17212356.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81 [17671132.001]
  • [Cites] J Clin Pharmacol. 2007 Sep;47(9):1138-51 [17766700.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4127-36 [17827463.001]
  • [Cites] J Neurooncol. 2000 Apr;47(2):109-15 [10982151.001]
  • (PMID = 20156802.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Indoles; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; UC96G28EQF / enzastaurin
  • [Other-IDs] NLM/ PMC2940647
  •  go-up   go-down


15. Han SJ, Yang I, Ahn BJ, Otero JJ, Tihan T, McDermott MW, Berger MS, Prados MD, Parsa AT: Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients. Cancer; 2010 Mar 1;116(5):1358-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
  • BACKGROUND: Primary gliosarcoma (PGS) is a rare central nervous system tumor with limited experience reported in the literature.
  • A total of 10 patients received radiotherapy with concurrent and adjuvant temozolomide chemotherapy, and 8 patients received radiotherapy alone or in combination with other chemotherapeutic agents.
  • Patients with gliosarcomas resembling meningioma were found to have a significantly prolonged median survival compared with patients harboring gliosarcoma resembling glioblastoma multiforme (16 months vs 9.6 months; P = .011).
  • The type mimicking the appearance of a meningioma appears to carry a significantly more favorable prognosis, most likely due to an increased chance at achieving macroscopic total resection.
  • [MeSH-major] Brain Neoplasms / therapy. Gliosarcoma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20052717.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


16. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG: Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther; 2000 Feb;1(2):195-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Between December 1996 and September 1998, 13 patients with advanced recurrent malignant brain tumors (9 with glioblastoma multiforme, 1 with gliosarcoma, and 3 with anaplastic astrocytoma) were treated with a single intratumoral injection of 2 x 10(9), 2 x 10(10), 2 x 10(11), or 2 x 10(12) vector particles (VP) of a replication-defective adenoviral vector bearing the herpes simplex virus thymidine kinase gene driven by the Rous sarcoma virus promoter (Adv.RSVtk), followed by ganciclovir (GCV) treatment.
  • [MeSH-major] Adenoviridae / genetics. Antiviral Agents / pharmacology. Brain Neoplasms / genetics. Brain Neoplasms / therapy. Ganciclovir / pharmacology. Genetic Therapy. Simplexvirus / enzymology. Thymidine Kinase / genetics
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / mortality. Astrocytoma / therapy. Avian Sarcoma Viruses / genetics. Combined Modality Therapy. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Genetic Vectors / administration & dosage. Glioblastoma / diagnostic imaging. Glioblastoma / genetics. Glioblastoma / mortality. Glioblastoma / therapy. Gliosarcoma / genetics. Gliosarcoma / mortality. Gliosarcoma / therapy. Humans. Male. Middle Aged. Promoter Regions, Genetic. Radiography. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10933931.001).
  • [ISSN] 1525-0016
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


17. Tang P, Roldan G, Brasher PM, Fulton D, Roa W, Murtha A, Cairncross JG, Forsyth PA: A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neurooncol; 2006 Jul;78(3):311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological subtypes were: 16 (59%) glioblastoma multiforme (GBM), malignant astrocytoma (5 patients), malignant mixed glioma (5 patients), and glioblastoma/gliosarcoma (1 patient).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Anorexia / chemically induced. Carboplatin / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Fatigue / chemically induced. Female. Headache / chemically induced. Humans. Male. Middle Aged. Nausea / chemically induced. Tamoxifen / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1992 Oct;31(4):717-24; discussion 724 [1407458.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Neurooncol. 1996 Feb;27(2):149-55 [8699237.001]
  • [Cites] J Neurooncol. 1991 Apr;10(2):139-44 [1654401.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] J Natl Cancer Inst. 1986 Jun;76(6):1243-6 [3458960.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7134-8 [2224848.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):619-22 [9816211.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):147-55 [11206010.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):1024-32 [8847567.001]
  • [Cites] Neurosurgery. 1991 Dec;29(6):880-6; discussion 886-7 [1758601.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;30(1):21-4 [1586976.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1669-74 [15746072.001]
  • [Cites] Neurology. 2001 Jan 9;56(1):118-20 [11148250.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3119-24 [1591725.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Arch Neurol. 1999 Jun;56(6):703-8 [10369310.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):725-9; discussion 729-30 [1407459.001]
  • [Cites] J Neurooncol. 1998 May;38(1):59-68 [9540058.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):594-600 [2398390.001]
  • [Cites] Neurosurgery. 1992 Jun;30(6):897-902; discussion 902-3 [1377370.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):409-22 [10458260.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Jun;100(2):89-93 [9746294.001]
  • [Cites] J Neurooncol. 1994;19(1):69-74 [7815106.001]
  • [Cites] Cancer Treat Rev. 2004 Dec;30(8):695-706 [15541579.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):588-93 [10944597.001]
  • [Cites] J Cancer Res Clin Oncol. 1999 Aug-Sep;125(8-9):481-6 [10480340.001]
  • [Cites] Annu Rev Biochem. 1989;58:137-71 [2570548.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23 ):4779-86 [15570079.001]
  • [Cites] Cancer Res. 1985 Jun;45(6):2462-5 [3157445.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Dec;15(6):1027-52 [11770297.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1571-6 [8453625.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6790-6 [1458467.001]
  • (PMID = 16710748.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen; BG3F62OND5 / Carboplatin
  •  go-up   go-down


18. Agarwal A, Jaye DL, Giegerman CM, Bellamkonda RV: Rational identification of a novel peptide for targeting nanocarriers to 9L glioma. J Biomed Mater Res A; 2008 Dec 1;87(3):728-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report that liposomal nanocarriers coated with a novel oligopeptide enhance uptake by 9L gliosarcoma.
  • The ability of RSI coated liposomes to facilitate drug uptake and cytotoxicity was compared with conventional liposomal nanocarriers and controls.
  • In addition, plasma clearance profiles of the RSI peptide coupled liposomal nanocarriers were evaluated in adult immuno-competent rats.
  • RSI peptide-coupled liposomal nanocarriers enhanced drug uptake by 9L cells by 500% compared with conventional liposomal nanocarriers, and significantly increased cytotoxicity.
  • [MeSH-major] Drug Carriers / pharmacokinetics. Gliosarcoma / metabolism. Liposomes / pharmacokinetics. Nanostructures. Peptides / pharmacokinetics
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacokinetics. Doxorubicin / pharmacokinetics. Male. Rats. Rats, Inbred F344. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2008.
  • (PMID = 18200546.001).
  • [ISSN] 1552-4965
  • [Journal-full-title] Journal of biomedical materials research. Part A
  • [ISO-abbreviation] J Biomed Mater Res A
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK064399; United States / NIDDK NIH HHS / DK / DK60647
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Liposomes; 0 / Peptides; 80168379AG / Doxorubicin
  •  go-up   go-down


19. Korones DN, Benita-Weiss M, Coyle TE, Mechtler L, Bushunow P, Evans B, Reardon DA, Quinn JA, Friedman H: Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Cancer; 2003 Apr 15;97(8):1963-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Temozolomide may prove more effective in combination with other agents.
  • METHODS: The authors conducted a Phase I study of temozolomide in combination with escalating doses of oral etoposide (VP-16) to determine the maximum tolerated doses of these two agents when given together.
  • Diagnoses included glioblastoma (n = 19), gliosarcoma (n = 3), anaplastic astrocytoma (n = 5), and anaplastic oligoastrocytoma (n = 2).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioma / drug therapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Dose-Response Relationship, Drug. Etoposide / administration & dosage. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12673724.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


20. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer; 2000 Sep;83(5):588-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse.
  • Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Brain Neoplasms / drug therapy. Dacarbazine / analogs & derivatives. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Procarbazine / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Quality of Life. Recurrence. Time Factors

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Cancer Research Campaign.
  • [Cites] J Neurosurg. 1974 Mar;40(3):365-71 [4360491.001]
  • [Cites] West J Med. 1998 Feb;168(2):114-20 [9499745.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):711-28 [3001488.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):5846-52 [3664486.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2420-3 [2555038.001]
  • [Cites] Control Clin Trials. 1989 Dec;10(4):407-15 [2691207.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;26(6):429-36 [2225314.001]
  • [Cites] Neurology. 1990 Nov;40(11):1743-6 [2172864.001]
  • [Cites] Br J Cancer. 1992 Feb;65(2):287-91 [1739631.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Eur J Cancer. 1993;29A(7):940-2 [8499146.001]
  • [Cites] J Clin Epidemiol. 1994 Jan;47(1):81-7 [8283197.001]
  • [Cites] J Neurooncol. 1994;20(2):165-76 [7807193.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] Baillieres Clin Neurol. 1996 Jun;5(2):371-93 [8781278.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] Qual Life Res. 1996 Dec;5(6):555-67 [8993101.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2236-41 [9038604.001]
  • [Cites] Qual Life Res. 1997 Mar;6(2):103-8 [9161109.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(6):484-8 [9332462.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • (PMID = 10944597.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] SCOTLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 35S93Y190K / Procarbazine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2363506
  •  go-up   go-down


21. Chen JH, Chen KY, Ma HI, Yu CP, Nieh S, Lee HS, Jin JS: Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma. Chin J Physiol; 2010 Aug 31;53(4):234-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma.
  • Gliosarcoma is a very rare primary neoplasm of the central nervous system classified as a variant of glioblastoma.
  • Cortactin, fascin and survivin have been found in several human cancers to play important roles in tumor progression, but the expression pattern of these biomarkers in gliosarcoma is unclear.
  • Immunostaining for cortactin, fascin and survivin was assessed in 6 surgical specimens of brain gliosarcoma, and the relationship between the expression of these biomarkers and tumor size or clinical parameters were examined.
  • Five of our six patients with gliosarcoma survived 3-17 months.
  • Our results demonstrated that over-expression of cortactin, fascin and survivin is associated with malignant transformation of brain gliosarcoma.
  • Development of drugs that target cortactin, fascin and survivin expression may be therapeutic to patients with gliosarcoma.
  • [MeSH-major] Brain Neoplasms / pathology. Carrier Proteins / analysis. Cortactin / analysis. Gliosarcoma / pathology. Inhibitor of Apoptosis Proteins / analysis. Microfilament Proteins / analysis
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21793333.001).
  • [ISSN] 0304-4920
  • [Journal-full-title] The Chinese journal of physiology
  • [ISO-abbreviation] Chin J Physiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carrier Proteins; 0 / Cortactin; 0 / Inhibitor of Apoptosis Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


22. Higashino T, Inamura T, Kawashima M, Ikezaki K, Miyazono M, Yoshiura T, Iwaki T, Fukui M: A lateral ventricular gliosarcoma arising in an ependymoma. Clin Neuropathol; 2001 Sep-Oct;20(5):219-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A lateral ventricular gliosarcoma arising in an ependymoma.
  • OBJECTIVE: We describe a 29-year-old man with gliosarcoma in the lateral ventricle.
  • Computed tomography and magnetic resonance imaging localized the tumor to the right lateral ventricle and showed heterogeneous enhancement with administration of contrast agents.
  • Histologic examination disclosed gliosarcoma arising by malignant transformation of an ependymoma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Ependyma / pathology. Gliosarcoma / pathology. Lateral Ventricles / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic / pathology. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ependymoma.
  • Genetic Alliance. consumer health - Gliosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11594507.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


23. Oshiro S, Tsugu H, Komatsu F, Ohmura T, Ohta M, Sakamoto S, Fukushima T, Inoue T: Efficacy of temozolomide treatment in patients with high-grade glioma. Anticancer Res; 2009 Mar;29(3):911-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: The subjects comprised ten patients with high-grade glioma [glioblastoma multiforme (GBM), n=3, gliosarcoma (GS), n=1, anaplastic oligodendroglioma (AO), n=3, anaplastic mixed oligoastrocytoma (AOA), n=1, and anaplastic ependymoma (AE), n=2].
  • RESULTS: Partial response (PR) to TMZ therapy was achieved by four out of the ten patients (objective response rate, 40%), while three patients displayed stable disease (SD) and three showed disease progression (PD).
  • Assessing the true efficacy of TMZ will require a larger study with comparison of long-term outcomes between other agents or combined therapeutic modalities.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Gliosarcoma / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Combined Modality Therapy. Dacarbazine / administration & dosage. Dacarbazine / analogs & derivatives. Etoposide / administration & dosage. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Treatment Outcome. Tumor Necrosis Factor-alpha / therapeutic use

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414327.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


24. Rao RD, Thomé SD, O'Fallon J, Earle JD, Dinapoli RP, Buckner JC: Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas. Int J Radiat Oncol Biol Phys; 2002 Jun 1;53(2):376-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Alkylating / adverse effects. Carmustine / adverse effects. Dose Fractionation. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / pathology. Astrocytoma / radiotherapy. Brain Diseases / etiology. Combined Modality Therapy. Drug Administration Schedule. Female. Gliosarcoma / drug therapy. Gliosarcoma / mortality. Gliosarcoma / pathology. Gliosarcoma / radiotherapy. Humans. Male. Middle Aged. Pilot Projects. Survival Rate. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12023142.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


25. Kondo A, Goldman S, Lulla RR, Mania-Farnell B, Vanin EF, Sredni ST, Rajaram V, Soares MB, Tomita T: Longitudinal assessment of regional directed delivery in a rodent malignant glioma model. J Neurosurg Pediatr; 2009 Dec;4(6):592-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Direct delivery of chemotherapeutic agents for the treatment of brain tumors is an area of focus in the development of therapeutic paradigms because this method of delivery circumvents the blood-brain barrier without causing adverse systemic side effects.
  • Few studies have investigated longitudinal tumor response to this type of therapy.
  • In this study, the authors examined the time course of tumor response to direct delivery of a chemotherapeutic agent in a rodent malignant glioma model.
  • Rat 9L gliosarcoma cells expressing a luciferase gene were inoculated into adult male rat striata.
  • Ten days following surgery the animals were randomly divided into 4 groups.
  • Histopathologically, 6 of 12 CED-treated animals exhibited no residual tumor at the end point of the study.
  • CONCLUSIONS: Direct and systemic delivery of carboplatin was examined to determine how the method of drug delivery affects tumor growth.
  • The present report is one of the first in vivo studies to examine the time course of tumor response to direct drug delivery.
  • The results indicate that direct drug delivery may be a promising option for treating gliomas.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Brain Neoplasms / drug therapy. Carboplatin / administration & dosage. Drug Delivery Systems / methods. Gliosarcoma / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Luciferases. Luminescent Agents. Male. Rats. Survival Analysis. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19951051.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Luminescent Agents; BG3F62OND5 / Carboplatin; EC 1.13.12.- / Luciferases
  •  go-up   go-down


26. Schäfer C, Fels C, Brucke M, Holzhausen HJ, Bahn H, Wellman M, Visvikis A, Fischer P, Rainov NG: Gamma-glutamyl transferase expression in higher-grade astrocytic glioma. Acta Oncol; 2001;40(4):529-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since GGT expression and its role in malignant glioma biology remain largely unknown, we investigated this phenomenon by immunostaining 26 higher-grade human astrocytic gliomas (WHO grades III and IV) with a monoclonal anti-GGT-antibody (138H11).
  • Further, human pancreatic GGT cDNA was used for liposome-mediated transfection of 9L gliosarcoma cells.
  • GGT-expressing and control 9L cells were cultured in media containing different amounts of essential amino acids and/or cytotoxic agents.
  • Human tumors were strongly GGT-positive in 6 of 7 cases of grade III astrocytoma, and in 12 of 19 grade IV astrocytoma (glioblastoma multiforme, GBM) cases.
  • No significant difference in numbers of viable cells of either clone was found in media containing the alkylating drug BCNU (5-200 microg/ml).
  • [MeSH-major] Glioblastoma / enzymology. Neoplasm Proteins / biosynthesis. Nerve Tissue Proteins / biosynthesis. gamma-Glutamyltransferase / biosynthesis
  • [MeSH-minor] Adult. Aged. Animals. Antibodies, Monoclonal / immunology. Antineoplastic Agents, Alkylating / pharmacology. Brain / enzymology. Carmustine / pharmacology. Cell Division. Clone Cells / drug effects. Clone Cells / metabolism. Clone Cells / pathology. Culture Media / pharmacology. Cysteine / pharmacology. DNA, Complementary / genetics. Drug Resistance, Neoplasm. Enzyme Induction. Female. Gliosarcoma / pathology. Glutamine / pharmacology. Humans. Liposomes. Male. Microscopy, Immunoelectron. Middle Aged. Rats. Recombinant Fusion Proteins / biosynthesis. Transfection. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / enzymology

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CYSTEINE .
  • Hazardous Substances Data Bank. Glutamine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11504314.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents, Alkylating; 0 / Culture Media; 0 / DNA, Complementary; 0 / Liposomes; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Recombinant Fusion Proteins; 0RH81L854J / Glutamine; EC 2.3.2.2 / gamma-Glutamyltransferase; K848JZ4886 / Cysteine; U68WG3173Y / Carmustine
  •  go-up   go-down






Advertisement